The objective of this study is to evaluate the safety, tolerability and pharmacokinetic of single/multiple ascending oral doses of ASP8302 in non-elderly healthy Japanese male and female subjects.

Inclusion Criteria:

• Body weight at screening: ≥ 50.0 kg and < 80.0 kg for male, ≥ 40.0 kg and < 70.0 kg for female.
• Body-mass index (BMI) at screening: ≥ 17.6 kg/m2 and < 26.4 kg/m2 [BMI = Body weight (kg) ÷ {Body height (m)2}].

Exclusion Criteria:

• Subjects who participated or are scheduled to participate in any clinical trials or post-marketing studies within 120 days before screening test or during the screening test to the hospital admission (Day -2).
• Subjects who conducted or is scheduled to conduct any of the blood donation or blood drawing in designated period before Day -2
• Subject who received or is scheduled to receive any medications within seven days before the hospital admission.
• Any deviation from any of the normal range of blood pressure, pulse rate, body temperature and standard 12-lead electrocardiogram at screening or on the day of hospital admission (Day -1).
• Subject who meets any of the criteria for laboratory tests at screening or on the day of hospital admission (Day -2).
• Any deviation from the normal range of routine 12-lead electrocardiogram at screening.
• Subjects with a complication or history of drug allergies.
• Subjects who developed upper gastrointestinal symptoms within seven days before the hospital admission.
• Subjects with a complication or history of hepatic disease.
• Subjects with a complication or history of cardiac disease.
• Subjects with a complication or history of respiratory disease except for history of asthma in childhood.
• Subjects with a complication or history of gastrointestinal disease except for a history of appendicitis.
• Subjects with a history of gastrointestinal resection except for appendicitis.
• Subjects with a complication or history of renal disease except for a history of calculus.
• Subjects with a complication or history of endocrine disease.
• Subjects with a complication or history of cerebrovascular disease.
• Subjects with a complication or history of malignant tumor.
• Subjects who received ASP8302 previously.
• Subjects who have a habit of excessive smoking or drinking alcohol.

Access to anonymized individual participant level data will not be provided for this trial. Further details on Astellas' data sharing policy can be found at https://www.clinicaltrials.astellas.com/transparency/.